Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany.
J Nucl Med. 2011 Mar;52(3):393-400. doi: 10.2967/jnumed.110.083683. Epub 2011 Feb 14.
PET studies with biomarkers of regional neuronal activity (cerebral glucose metabolism or blood flow [CBF]) and amyloid-β (Aβ) depositions provide complementary information for the early diagnosis of dementia and follow-up of patients with dementia. We investigated the validity of relative regional CBF estimates (R(1)) gained from pharmacokinetic analyses of (11)C-labeled Pittsburgh compound B ((11)C-PIB) PET studies as a marker of neuronal activity and neurodegeneration.
Twenty-two patients with cognitive impairment (16 patients with early Alzheimer disease) underwent (18)F-FDG and (11)C-PIB PET studies for the assessment of regional glucose metabolism and Aβ load. Parametric images of R(1) (relative CBF) and binding potential (BP(ND); Aβ load) were generated by 2-step simplified reference tissue model (SRTM2) analyses of dynamic (11)C-PIB data. Volume-of-interest and voxel-based statistical analyses were performed to investigate the association between normalized (18)F-FDG uptake and (11)C-PIB R(1) and the correlation of these measures with symptom severity (Mini-Mental State Examination [MMSE] scores) in patients with Alzheimer disease.
SRTM2 analyses provided high-quality (11)C-PIB R(1) images that were comparable to (18)F-FDG PET images. Regional (11)C-PIB R(1) values strongly correlated with normalized regional (18)F-FDG uptake when correlations were calculated separately for each patient (R(2) [mean ± SD], 0.73 ± 0.11) or across all regions of all patients (R(2), 0.62). A regression model including (18)F-FDG uptake, subject identification, and region grouping (into cortical, subcortical, and limbic regions to allow for possible differences in flow/metabolism coupling) accounted for 86% of total (11)C-PIB R(1) variability. Voxel-based correlation analyses of (18)F-FDG uptake and (11)C-PIB R(1) with MMSE scores revealed similar core findings of positive correlations in the posterior cingulate gyrus/precuneus and negative correlations (preserved activity) in the bilateral sensorimotor cortex. There was no correlation between Aβ load (BP(ND)) and MMSE scores.
These results strongly suggest that (11)C-PIB R(1) can serve as a complementary biomarker of neuronal activity and, thus, neurodegeneration in addition to Aβ load given by (11)C-PIB BP(ND). Further studies are needed to validate the diagnostic value of dual-biomarker (11)C-PIB PET studies in comparison with combined (18)F-FDG and (11)C-PIB PET studies. Compared with the latter, dual-biomarker (11)C-PIB PET greatly reduces costs and burden for patients.
探讨利用(11)C-标记的匹兹堡化合物 B((11)C-PIB)PET 研究中的基于区域神经元活动的生物标志物(脑葡萄糖代谢或血流[CBF])的相对区域 CBF 估计值(R(1))作为神经元活性和神经退行性变的标志物的有效性。
22 例认知障碍患者(16 例早期阿尔茨海默病患者)接受了(18)F-FDG 和(11)C-PIB PET 研究,以评估区域葡萄糖代谢和 Aβ负荷。通过动态(11)C-PIB 数据的 2 步简化参考组织模型(SRTM2)分析生成 R(1)(相对 CBF)和结合潜能(BP(ND);Aβ负荷)的参数图像。进行基于体素和基于感兴趣区的统计分析,以研究阿尔茨海默病患者中归一化(18)F-FDG 摄取与(11)C-PIB R(1)之间的关联,以及这些测量值与症状严重程度(简易精神状态检查[MMSE]评分)的相关性。
SRTM2 分析提供了高质量的(11)C-PIB R(1)图像,这些图像与(18)F-FDG PET 图像相似。当分别为每个患者(R(2)[平均值±标准差],0.73±0.11)或为所有患者的所有区域(R(2),0.62)计算相关性时,区域(11)C-PIB R(1)值与归一化区域(18)F-FDG 摄取强烈相关。包括(18)F-FDG 摄取,患者识别和区域分组(进入皮质,皮质下和边缘区域,以允许可能存在的血流/代谢偶联差异)的回归模型可以解释(11)C-PIB R(1)总变异的 86%。基于体素的(18)F-FDG 摄取与(11)C-PIB R(1)与 MMSE 评分的相关性分析揭示了在后扣带回/顶下小叶和双侧感觉运动皮层中存在正相关(保存的活性)的相似核心发现。Aβ负荷(BP(ND))与 MMSE 评分之间没有相关性。
这些结果强烈表明,(11)C-PIB R(1)可以作为除(11)C-PIB BP(ND)给出的 Aβ负荷以外的神经元活性和神经退行性变的补充生物标志物。需要进一步的研究来验证与(18)F-FDG 和(11)C-PIB PET 联合研究相比,双重生物标志物(11)C-PIB PET 在诊断价值方面的价值。与后者相比,双重生物标志物(11)C-PIB PET 大大降低了患者的成本和负担。